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Abstract
Old age is associated with characteristic changes of the immune system contributing to higher
incidence and severity of many infectious diseases. Particularly within the T cell compartment latent
infection with human Cytomegalovirus (CMV) is contributing to and accelerating
immunosenescence. However, latent CMV infection and reactivation usually does not cause overt
symptoms in immunocompetent elderly persons indicating immunological control of disease. Little
is still known about the clonal composition of CMV-specific T cell responses in donors of different
age. We therefore analyzed CD8+ T cells specific for an immunodominant pp65-derived nonamer-
peptide (NLVPMVATV; CMVNLV) in different age-groups. Independent of donor age CMVNLV-
specific CD8+ T cells preferentially use the V beta family 8. This family has monoclonal expansions
in the majority of donors after stimulation of CD8+ T cells with the peptide. By sequencing the
CDR3 region of the T cell receptor we demonstrated that CMVNLV-specific, BV8+ CD8+ T cells
share the conserved CDR3-sequence motif SANYGYT in donors of all age groups. Interestingly, a
second conserved clonotype with the CDR3-sequence motif SVNEAF appears in middle-aged and
elderly donors. This clonotype is absent in young individuals. The age-related clonotype SVNEAF
binds to the pMHC-complex with higher avidity than the clonotype SANYGYT, which is
predominant in young adults. The dominance of this high avidity clonotype may explain the lack of
overt CMV-disease in old age.
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Background
Ageing is associated with an increase in the incidence and
severity of many infectious diseases. The most common
infections in the elderly are influenza, infections with
Streptococcus pneumoniae, infections of the skin and also
of the urogenital tract [1]. In addition, reactivation of
latent viruses and bacteria such as Varicella-Zoster-Virus
leading to Herpes zoster [2,3] and Mycobacterium tuber-
culosis [4,5] are more frequent in old age. This may be due
to decreased immunosurveillance as well as to other fac-
tors such as age-associated diseases, poor nutrition,
chronic renal failure and institutionalization.
Cytomegalovirus (CMV) is a human beta-herpesvirus
with a prevalence of 60–100% in the adult population.
The link between CMV-infection, immunosenescence and
longevity has recently been a subject of great interest [6,7].
Despite frequent reactivation of latent CMV in the elderly
as suggested by increased anti-CMV antibodies and viral
shedding in the urine [8] there are no reports about overt
CMV-disease in immunocompetent elderly persons. T
cells are essential for the control of viral replication,
spread and disease [9-12]. In CMV-seropositive elderly
persons up to 25% of the total CD8+ T cell pool can be
specific for CMV with the epitope NLVPMVATV of the
pp65 matrix protein (CMVNLV) being immunodominant
[13]. These CMV-specific cells show a highly differenti-
ated effector phenotype [14-16] and express markers for
cytotoxicity [14,16]. They are proinflammatory [16], and
to a high degree clonally expanded [13,17,18]. This has
led to the suggestion that CMV-specific T cell clones take
up a lot of space and may therefore be responsible for the
loss of T cells of other specificities, such as for instance for
Epstein-Barr virus (EBV) [19]. The proinflammatory prop-
erties of the steadily increasing number of CMV-specific T
cells may represent an additional problem, as age-related
subclinical inflammatory processes termed "inflamm-age-
ing" can be enhanced [20]. Inflammation is known to
support the development and progression of age-related
diseases such as for instance Alzheimer's disease [21]. In
longitudinal studies on octo- and nonagenerians CMV-
seropositivity has also been linked to the so-called
"immune-risk phenotype" and with increased mortality
[22,23].
Despite the obvious importance of CMV infection in old
age little is known about the clonal composition of CMV-
specific T cells in apparently healthy elderly persons. We
therefore analyzed the clonal composition of CD8+ T cells,
which are specific for the HLA-A*0201-restricted, immun-
odominant pp65-derived epitope NLVPMVATV [24,25] in
persons of different age.
Results and discussion
Stimulation of CD8+ T cells with CMVNLV-peptide leads to 
expansion of CMVNLV-specific cells with restricted V beta 
usage
CD8+  T cells were isolated from peripheral blood of
healthy donors of different age groups and were cultivated
for 14 days in the presence of the immunodominant, HLA
A*0201-restricted CMV-derived peptide NLVPMVATV, IL-
2 and autologous irradiated feeder cells. The frequencies
of CMVNLV-specific CD8+ T cells were determined ex vivo
and were 0.6% ± 0.7, 1.7% ± 0.8, and 1.7 ± 1.9, for young,
middle-aged and elderly donors respectively (mean ± SD;
p < 0.05 for young vs. middle-aged and young vs. old).
Irrespective of age, high frequencies of CMVNLV-specific T
cells were obtained for most donors after 14 days of cul-
ture (mean 77.0% ± 14.9). Figure 1A shows examples of
pentamer-FACS-stainings before and after culture for one
young, one middle-aged and one elderly donor.
In order to analyze the T cell receptor (TCR) repertoire
CMVNLV-specific T cells were further purified using pen-
tamers and microbeads reaching a purity of CMVNLV-spe-
cific CD8+ T cells above 95% for all samples. Spectratyping
of the CDR3 (complementary determining region 3)
region of the TCR beta chain was performed as previously
described [26,27]. CMVNLV-specific CD8+ T cells preferen-
tially used BV 8 and BV 13 after culture (Figure 1B). 64%
and 59% of all donors had monoclonal expansions (clon-
ality score 3) in BV8 or BV13, respectively. No differences
in the spectratype scores were observed between the differ-
ent age groups (data not shown). Previous work analyzing
the V beta usage of CMVNLV-specific T cells shows that the
broad repertoire of CMV-specific T cells, which is stimu-
lated during primary infection rapidly focuses on individ-
ual BV families within the first weeks after infection [28].
Restimulation in vitro does not alter the T cell repertoire
[29,30]. In accordance with our results it has been shown
that CMVNLV-specific T cells preferentially use BV 8, 13
and 6 in healthy adults as well as in immunosuppressed
patients [28-33].
The sequence of the CDR3 region of BV8+ T cell receptors 
of CMVNLV-specific CD8+ T cells changes with age
In order to characterize the repertoire of CMVNLV-specific
CD8+ T cells in more detail we sequenced the CDR3-
region of the T cell receptor of in vitro expanded and puri-
fied BV8+ T cells. We chose this BV family as the most
dominant family within CMVNLV-specific T cells. TCR
sequences were amplified from cDNA and were cloned
into a bacterial vector. Plasmid-DNA was isolated and
sequenced by standard procedures. Figure 2 shows the
amino acid sequences of the antigen binding site for
CMVNLV-specific T cell receptors. In accordance with liter-
ature on CDR3-sequences from healthy and HIV-infected
adults [30-33] the highly conserved CDR3-sequence motifImmunity & Ageing 2008, 5:14 http://www.immunityageing.com/content/5/1/14
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Preferential expansion of BV8 and BV13 CD8+ T cells after stimulation with CMVNLV-peptide Figure 1
Preferential expansion of BV8 and BV13 CD8+ T cells after stimulation with CMVNLV-peptide. Cells were stimu-
lated in vitro for 14 days with CMVNLV-peptide in the presence of IL-2 and autologous, irradiated PBMC. (A) CD8+ T cells were 
stained with APC-conjugated pentamers containing the CMVNLV-peptide. Representative examples are shown for one young, 
one middle-aged and one elderly donor directly ex vivo and after 14 days of culture. Percentages of CD8+ CMVNLV-specific T 
cells are indicated. (B) After 14 days of culture CMVNLV-specific T cells were further purified from the expanded cells using 
MACS-technology. Spectratyping was performed from PCR-products of 24 individual V beta families for 31 donors (10 young, 
7 middle-aged, 14 elderly). In the right panel examples for the different clonality and intensity scores (see Methods) are shown. 
Clonality and intensity scores are added to obtain a total score. For each BV family the percentage of donors with a total score 
above 5 is shown.
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Sequence analysis of the CDR3-region of BV8+ CMVNVL-specific T cells from different age-groups Figure 2
Sequence analysis of the CDR3-region of BV8+ CMVNVL-specific T cells from different age-groups. PCR-products 
were generated of the relevant TCR-sequences and cloned into a bacterial vector. 4 arbitrarily chosen bacterial clones are 
shown for each donor. Two dominant sequences and a variety of individually used sequences were detected. Conserved 
sequences were categorized as "SANYGYT" (light grey) and "SVNEAF" (dark grey). Discordance of one or two amino acids 
from the conserved dominant sequences was considered as minor variation, and these clones were included in these two cat-
egories. Sequences with greater variations were considered as private clones.
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SANYGYT was detected in all young donors. 72% of all
bacterial clones derived from young individuals share this
sequence motif. 28% of all sequences were private, which
means that they were not conserved between different
donors. However, we now show that with increasing age
the dominance of the clonotype SANYGYT decreases, as
this sequence is only present in 21% or 36% of the bacte-
rial clones obtained from middle-aged and elderly
donors, respectively. Interestingly, a second dominant
clonotype with a shorter CDR3-region and the CDR3-
sequence motif SVNEAF appears in middle-aged and eld-
erly donors. Exchanges of one or two aminoacids were
considered as minor variations. The age-dependency of
CDR3-sequences was analyzed in a cross-table with calcu-
lation of Pearson-Chi-square and was shown to be signif-
icant (p < 0.01). The CDR3-sequence motif SVNEAF has
been detected in previous studies in adult persons [32,33],
but was not identified as a conserved sequence. None of
this previous work refers to the age of the donors and it
can thus be assumed that most of the donors studied were
young adults. We now for the first time report that a
CMVNLV-specific BV8+ clonotype with the CDR3 sequence
SVNEAF becomes dominant with increasing age, while
the frequency of the "youth related" clonotype SANYGYT
decreases.
CMV-specific BV8+ CD8+ T cells with the TCR-sequence 
SVNEAF have a higher antigen avidity than corresponding 
cells with the sequence SANYGYT
In order to further investigate CMVNLV-specific BV8+ T cells
with different conserved CDR3-sequences we analyzed
the antigen avidity of T cells with either the CDR3-
sequence-motif SANYGYT or SVNEAF. For this purpose
cultures were selected, in which BV8+ CMVNLV-specific T
cells had a monoclonal profile with the CDR3-sequence
SANYGYT or SVNEAF, respectively. Binding and dissocia-
tion of pMHC pentamers to the T cell receptor of in vitro
expanded BV8+ CMVNLV-specific T cells were analyzed.
Staining with increasing amounts of CMVNLV-pentamer
shows that pentamer binding and therefore avidity of the
TCR is significantly increased for T cells with the CDR3-
sequence SVNEAF compared to corresponding cells with
the CDR3-sequence SANYGYT (Figure 3A; note the loga-
rithmic scale). The kinetics of TCR-pMHC dissociation
provides information on the stability of the TCR-pMHC
complexes. T cells were stained with saturated amounts of
CMVNLV-pentamer and anti-HLA-A2*0201 antibodies
were added to prevent re-binding of dissociated pentam-
ers. We could show that CMV-pentamers dissociated more
slowly from CMV-specific CD8+ T cells with the CDR3-
sequence SVNEAF, whereas TCR-pMHC complexes on
cells with the sequence SANYGYT were less stable (Figure
3B). In summary these data show that the interaction
between pMHC complexes and the TCR is stronger and
more stable for T cells that express a TCR with the antigen-
binding-motif SVNEAF indicating higher avidity of these
T cells.
High avidity CD8+ T cells are essential for clearance of
viral infections [34-37] and for the elimination of tumour
cells [38-40]. Therefore, anti-tumour vaccination aims to
induce high avidity tumour-specific T cells. In concord-
ance, immunotherapy for viral diseases such as EBV- or
CMV-reactivation and infection in immunosuppressed
patients after haematopoietic stem cell transplantation
benefits from selection of virus-specific T cells with high
avidity [41]. Regarding our data, the question arises, why
the high avidity clonotype SVNEAF is absent in young
individuals while it is dominant in a subset of the middle-
aged and elderly persons. In view of the well known
decline of immune function with age [42] it seems likely
that a subgroup of elderly persons suffers from high CMV-
activity and pronounced viral reactivation [8], which
necessitated the expansion of the high avidity BV8+
CMVNLV-specific clonotype for viral control. Due to its
high avidity this clonotype expands and presumably
exerts increased effector functions in vivo leading to pro-
tection from CMV-disease. However, accumulation of
CMV-specific T cells of this specific clonotype may be par-
ticularly prone to inhibit T cells of other specificities [19].
CMV-seropositivity has also been associated with non-
responsiveness to anti-influenza vaccination [43] and
with frailty [44]. The price for good protection against
CMV -as provided by CMV-specific cytotoxic T lyphocytes
with high avidity- might thus be accelerated immunose-
nescence and potentially lower responses to other patho-
gens.
Methods
Blood donors
Peripheral blood was obtained from healthy, CMV-serop-
ositive, HLA A*0201- positive donors of different age
groups (Table 1). A medical history was obtained and
only individuals without malignancies, acute diseases or
advanced stages of severe chronic diseases, such as chronic
inflammatory disease, atherosclerotic disease, congestive
heart failure, poorly controlled diabetes mellitus, renal or
hepatic disease or chronic obstructive pulmonary disease
and persons without immunosuppressive therapy were
included in the study. The study was approved by the local
ethical committee and all participants gave their written
informed consent. Peripheral blood mononuclear cells
(PBMC) were isolated by density gradient centrifugation
(FicollHypac; Amersham Biosciences). CMV-specific anti-
body levels were determined by enzyme-linked immuno-
sorbent assay (Enzygnost® anti-CMV/immunoglobulin G;
Dade Behring) according to the manufacturer's protocol.
Recent primary infection with CMV is associated with the
presence of low-avidity CMV-specific antibodies. In a flu-
orescence-based assay (Euroimmun) the avidity of CMV-Immunity & Ageing 2008, 5:14 http://www.immunityageing.com/content/5/1/14
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Figure 3 (see legend on next page)
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specific IgG was measured by analyzing the stability of the
antigen-antibody-complex in the presence of urea. Low-
avidity antibodies show a "relative avidity index" (RAI;
optical density in the presence of urea compared to optical
density without urea) of <40%. For all samples tested the
RAI was >45% indicating past infection and excluding
recent primary infection.
Cultivation of CD8+ T lymphocytes and enrichment of 
CMVNLV-specific T cells
CD8+  T cells were isolated using anti-CD8-conjugated
microbeads and the magnetic-activated cell sorting
(MACS) system (Milteny Biotech) according to the speci-
fications given by the manufacturer. CD8+ T cells were cul-
tivated in RPMI 1640 (Cambrex) supplemented with 10%
FCS (Sigma-Aldrich) and 1% penicillin-streptamycin
(Cambrex) at 37°C and 5% CO2. T cells were stimulated
for 14 days with 0.1 μg/ml of the immunodominant pep-
tide NLVPMVATV (Bachem) derived from the CMV-
encoded protein pp65 in the presence of IL-2 (20 ng/ml)
and irradiated (30 Gy) autologous PBMC in a CD8+ :
PBMC ratio of 1:1. IL-2 (20 ng/ml) was added every three
days and cells were restimulated with peptide and irradi-
ated autologous PBMC after 7 days. Percentages of
CMVNLV-specific CD8+ T cells were determined prior to
culture and after 14 days of stimulation by immunofluo-
rescence surface staining with APC-coupled pentamers
containing the CMVNLV  peptide (Pro5®  MHC, Proim-
mune). After 14 days of cultivation CMVNLV-specific CD8+
T cells were purified using APC-conjugated CMV-pen-
tamer, anti-APC-antibodies coupled with magnetic beads
and MACS-technology. Purity of CMVNLV-specific T cells
was >95% in all cases.
Isolation of RNA and cDNA synthesis
RNA was isolated from CMVNLV-specific T cells using the
RNeasy Plus Mini Kit (QIAGEN) and cDNA-synthesis was
performed using a Reverse Transcription system with
Oligo(dT)-primers (Promega).
CDR3 spectratyping of V beta families
PCR fragments were amplified from cDNA for 24 V beta
families (BV) and complementarity determining region
(CDR3) spectratyping was performed as previously
described [26,27]. Analysis of the raw data was performed
with the GeneScan 3.7 analysis software package (PE
Applied Biosystems) using the Local Southern method for
fragment size estimation [27]. The occurrence of domi-
nant clonal expansions was quantified for each V beta
family by assigning scores for clonality (1 = Gaussian dis-
tribution; 2 = several peaks; 3 = one peak; compare with
[28]) and intensity as measured in relative fluorescence
units (RFU) (0 = < 500 RFU; 1 = 500–3000 RFU; 2 =
3000–8000; 3 = >8000). If necessary, PCR-products were
diluted prior to spectratyping and the dilution factor was
taken into account for the calculation of the intensity
score. Diversity and intensity scores were added and BV
families with a total score of ≥ 5 were considered as pre-
dominant. This score equally weights monoclonal BV
families with intermediate intensity (3+2) as well as oligo-
clonal BV families with high intensity (2+3). Both catego-
ries as well as monoclonal BV families with high intensity
(3+3) were considered as predominant.
Higher antigen avidity of CMV-specific CD8+ T cells with the CDR3-sequence SVNEAF Figure 3 (see previous page)
Higher antigen avidity of CMV-specific CD8+ T cells with the CDR3-sequence SVNEAF. CMVNLV-specific CD8+ T 
cells were stimulated in vitro with CMVNLV-peptide for two weeks. Donors with a monoclonal profile of BV8+ CMVNLV-specific 
T cells with the CDR3-sequence SANYGYT or SVNEAF respectively were selected. BV8+ T cells were identified by FACS-
staining and results are shown for BV8+ gated, CMVNLV-specific-T cells only. (A) CMVNLV-specific BV8+ T cells were stained 
with different concentrations of CMVNLV-pentamer. The mean fluorescence intensity (MFI; note the logarithmic scale) of 
bound pentamer is indicated for donors with the CDR3-sequence SANYGYT (light grey) or SVNEAF (dark grey). n = 3; mean 
± SEM. * p < 0.05 (Student's t-test for unpaired data). (B) CMVNLV-specific CD8+ T cells were stained with saturated amounts 
of CMVNLV-pentamer (1.25 μg/ml) and the dissociation rates of pentamers from CMV-specific CD8+ T cells were determined 
for donors with the CDR3-sequence SANYGYT (light grey) or SVNEAF (dark grey). Dissociation of pentamers was assessed 
by FACS analysis at different time points (range 0–180 min). Mean fluorescence intensity (MFI) of pentamer-positive T cells at 
time point 0 (maximum pentamer binding) was considered as 100%. n = 3; mean ± SEM. * p < 0.05 (Student's t-test for 
unpaired data).
Table 1: Gender and age of blood donors
n male/female median age (years) age range (years)
young (≤ 39 y) 10 4/6 33 28–37
middle-aged (40–64 y) 7 3/4 49 42–53
elderly (≥ 65 y) 15 7/8 70 65–87Immunity & Ageing 2008, 5:14 http://www.immunityageing.com/content/5/1/14
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Bacterial cloning of TCR-sequences and sequence analysis
T cell receptor sequences of the BV8 family were amplified
using a forward primer specific for the BV8 family (5'
CGTTCCGATAGATGATTCAGG 3') and a reverse primer
(5' CTGGGTCCACTCGTCATTCT 3') located in the con-
stant region of the TCR beta chain. PCR fragments were
cloned into the pCR®-II-TOPO® vector (Invitrogen) via TA-
cloning and the vector was transformed into chemically
competent E. coli (One Shot TOP10, Invitrogen). For each
donor several positive clones were picked and plasmid
DNA was extracted using standard procedures (QIAprep
Spin Miniprep Kit, QIAGEN). TCR-sequences were deter-
mined by standard sequencing procedures (QIAGEN) and
sequence data were analyzed using the Bioedit Sequence
Alignment Editor 7.0.5.3.
Measurement of TCR binding kinetics
CMVNLV-specific CD8+ T cells were harvested after 14 days
of culture and used for pentamer binding and dissociation
assays as previously described [29,30] with minor modifi-
cations. Briefly, T cells were stained with increasing
amounts (range 0.1 to 5 μg/ml) of CMVNLV-pentamers.
Mean fluorescence intensity (MFI) of pentamer-binding
CD8+ T cells was measured by a FACSCalibur flow cytom-
eter (BD Pharmingen). For the analysis of pentamer disso-
ciation T cells were stained with saturated amounts of
CMVNLV-pentamers (1.25 μg/ml). 25 μg/ml unlabelled
anti-HLA-A2*0201 antibodies (clone BB7.2) were added
to prevent re-binding of dissociated pentamers. Dissocia-
tion of pentamers was assessed by FACS analysis at differ-
ent time points (range 0–180 min). The MFI of pentamer-
positive T cells at time point 0 (maximum pentamer bind-
ing) was considered as 100%.
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